1-9 of 9
Tomasz Szczudlo, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Attitudes and Perceptions of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Toward Treatment-Free Remission (TFR)

Carla Maria Boquimpani, MD, Tomasz Szczudlo, MD, Estella Mendelson, BSRN, MBA, Katy Benjamin, PhD, Tamás Masszi, MD PhD
Journal: Blood
Blood (2014) 124 (21): 4547.
https://doi.org/10.1182/blood.V124.21.4547.4547
Published: 2014
Journal Articles

Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib

Soo Young Choi, Sung-Eun Lee, Yun jeong Oh, Soo-Hyun Kim, Richard C. Woodman, Tomasz Szczudlo, MD, Saengsuree Jootar, MD, Hyeoung-Joon Kim, MD PhD, Sang Kyun Sohn, MD PhD, Joon Seong Park, MD, Sung-Hyun Kim, MD PhD, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1816.
https://doi.org/10.1182/blood.V124.21.1816.1816
Published: 2014
Journal Articles

Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Franck Emmanuel Nicolini, MD, PhD, Gabriel Etienne, MD, Dominique Bordessoule, Denis Caillot, MD, Coralie Belanger, Jean-Michel Cayuela, MD, Aude Charbonnier, Valerie Coiteux, MD, Agnès Guerci-Bresler, Viviane Dubruille, Thierry Lamy, MD, PhD, Francoise Huguet, Philippe Rousselot, MD, PhD, Michel Tulliez, Jean-Yves Cahn, Martine Gardembas-Pain, Laurence Legros, MD, Frederic Maloisel, Delphine Rea, MD, PhD, Hyacinthe Johnson-Ansah, MD, Pascal Lenain, Alain Delmer, MD, PhD, Marc Berger, MD, Tomasz Szczudlo, MD, Jim Wang, PhD, Mei Sheng Duh, MPH, ScD, Francois Guilhot, MD
Journal: Blood
Blood (2009) 114 (22): 3293.
https://doi.org/10.1182/blood.V114.22.3293.3293
Published: 2009
Journal Articles

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Philipp D. le Coutre, MD, Anna Turkina, Dong-Wook Kim, MD, PhD, Bernadeta Ceglarek, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, Pedro Enrique Dorlhiac-Llacer, David A Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Si-Tien Wang, Franck Emmanuel Nicolini, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 3286.
https://doi.org/10.1182/blood.V114.22.3286.3286
Published: 2009
Journal Articles

Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or —Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Franck Emmanuel Nicolini, MD, PhD, Dong-Wook Kim, MD, PhD, Bernadeta Ceglarek, Anna Turkina, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, Pedro Enrique Dorlhiac-Llacer, David A. Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Christine Bieri, MBA, Philipp D. le Coutre, MD
Journal: Blood
Blood (2009) 114 (22): 2201.
https://doi.org/10.1182/blood.V114.22.2201.2201
Published: 2009
Journal Articles

Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Philipp D. le Coutre, MD, Bernadeta Ceglarek, Anna Turkina, Dong-Wook Kim, MD, PhD, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, David A Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Ellison Dial, MBA, Franck Emmanuel Nicolini, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1115.
https://doi.org/10.1182/blood.V114.22.1115.1115
Published: 2009
Journal Articles

Nilotinib Treatment in Pediatric Patients (pts) with Philadelphia Chromosome- Positive (Ph+) Leukemia Refractory to Prior Tyrosine Kinase Inhibitor (TKI) Therapy: Results from Nilotinib Compassionate Use Program

Alan S. Wayne, MD, Carla Renata Macedo, MD, Tomasz Szczudlo, MD, Richard C. Woodman, MD
Journal: Blood
Blood (2008) 112 (11): 4264.
https://doi.org/10.1182/blood.V112.11.4264.4264
Published: 2008
Journal Articles

Occurrence of Pleural/Pericardial Effusions in Ph+ CML Patients Failing Prior Tyrosine Kinase Inhibitors (TKI) Before Starting Nilotinib – Retrospective Analysis upon Entry into the Nilotinib Compassionate Use Program

Philipp D. le Coutre, MD, Michael O’Dwyer, MD, FRCPI, FRCPath, Tomasz Szczudlo, MD, Richard C. Woodman, MD, Francis J. Giles, MD
Journal: Blood
Blood (2008) 112 (11): 4271.
https://doi.org/10.1182/blood.V112.11.4271.4271
Published: 2008
Journal Articles

Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis

Jeffrey H. Lipton, MD, PhD, Philipp D. le Coutre, MD, Jim Wang, PhD, Mindy Yang, PharmD, Tomasz Szczudlo, MD, Francis Giles, MD
Journal: Blood
Blood (2008) 112 (11): 3233.
https://doi.org/10.1182/blood.V112.11.3233.3233
Published: 2008